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We previously demonstrated in a side-by-side comparison with equivalent calcium and protein restriction that reduced energy intake is the major contributor to reductions in bone mineral density and serum estrogen levels seen with restriction of all nutrients (global food restriction) (2) . In addition, negative energy balance in humans and animals is associated with higher bone marrow adipogenesis, which often appears coincident with lower bone mass (10, 17) .
A fascinating line of research has emerged over the last decade detailing the role the sympathetic nervous system (SNS) plays in the regulation of bone mass. SNS activation has been shown to reduce osteoblast proliferation (43) and to stimulate bone resorption by increasing RANKL expression (19) ; over time, this can produce a loss of cancellous bone mass. Increased SNS activation may also play a role in ER-induced bone loss. Global food restriction can also increase norepinephrine release (47) , which is associated with increased bone resorption and decreased bone formation. Pharmacological ␤-blockade mitigates loss of cancellous bone in the context of stressful conditions such as disuse via hindlimb unloading in mature rats (4) , ER in adult mice (45) , and ovariectomy in exercising adult rats (7) . Several lines of evidence support SNS regulation of osteoblast function. Takeda et al. confirmed that osteoblasts express ␤-adrenergic receptors (43) . Wild-type mice given a ␤-adrenergic antagonist experience an increase in bone mass. Leptin-deficient mice (ob/ob) have low sympathetic activity but high vertebral bone mass; if a ␤-adrenergic agonist (isoproterenol) is administered, bone mass declines by 45% without affecting appetite (43) . In addition, ␤2-adrenergic receptor knockout mice have a high bone mass phenotype but no other endocrine abnormalities that affect bone metabolism (19) .
Leptin, a cytokine-like hormone principally produced by white adipocytes, is one of the important endocrine factors altered by ER. Although its principal function is the regulation of energy stores and body composition through negative feedback at the hypothalamic nuclei, leptin also has multiple effects on bone cell differentiation and function. The nature of leptin's effects on bone is somewhat controversial. Leptin that binds to its hypothalamic receptors demonstrates anti-osteogenic effects via the SNS signaling (18, 43) , but when physiological doses of leptin are administered peripherally, leptin exerts a bone protective effect by mitigating bone loss due to mechanical unloading, ovariectomy, or ER (4, 11, 21) . Expression of leptin receptors on the cells of osteoblastic lineage has been demonstrated, confirming that osteoblasts are targets for leptin action (16, 40, 46) . In addition to its positive effect on osteoblast differentiation (16) , leptin inhibits the expression of RANKL, synthesized by osteoblasts and an important stimulator of bone resorption, as well as enhances the expression of OPG, the decoy receptor for RANKL (27) .
We previously demonstrated that hindlimb unloading and global food restriction each independently produce a decrease in serum leptin, with the combined treatment resulting in undetectable serum leptin levels (3). When propranolol, a ␤-adrenergic receptor antagonist, is administered to hindlimbunloaded rats, this blockade of ␤-adrenergic signaling attenuates the unloading-induced decline in serum leptin and reductions in cancellous bone mass and bone formation rate (3). However, it remains unproven whether blocking ␤-adrenergic signaling attenuates ER-induced bone loss and increases in marrow adiposity and whether these effects are associated with concomitant mitigated reductions in circulating leptin. In the present study, we tested 1) whether ␤-adrenergic blockade attenuates decreases in serum leptin and bone mass and increases in marrow adiposity during dietary ER and 2) whether rescued circulating leptin is associated with this bone-loss attenuation.
MATERIALS AND METHODS
Animals and experimental design. Forty Sprague-Dawley virgin female rats, aged 4 mo at purchase (Harlan, Indianapolis,IN), were singly housed on a 12-h light-dark cycle and allowed to eat AIN93-M purified diet (Research Diets, New Brunswick, NJ) for 8 wk before the start of the experiment. The AIN93-M diet most closely matches National Research Council (NRC) recommendations for mature rat dietary requirements (38, 39) . Because we had previously observed a significant loss in volumetric bone mineral density (vBMD) in metaphyseal bone in adult rats switched from the chow fed by the vendor (Harlan Teklad 2018) to this AIN93-M diet, we tested an extended period of acclimation to this diet with weekly computed tomography scans. A stable proximal tibia vBMD (defined by two consecutive average vBMD values that change by Ͻ10 mg/cm 3 ) was observed by 6 wk; we chose to extend this dietary acclimation period to 8 wk.
Experimental design. Rats were block assigned first by cancellous vBMD at the end of acclimation and then by body weight into four groups of 10 animals each: ad libitum-fed controls (n ϭ 10 each) treated with vehicle (CONVEH) or ␤-blocker (CONBB), and energyrestricted rats (n ϭ 10 each) treated with vehicle (ERVEH) or ␤-blocker (ERBB). The CONVEH and the CONBB groups were fed ad libitum for the 12-wk protocol. Food intake for the CONVEH rats was measured each day. To achieve the 40% ER, ERVEH and ERBB rats were fed 0.61 g of the specially formulated diet (AIN-93M-E) for every 1 g of AIN-93M of the CONVEH group average consumption. A higher density of other nutrients in the modified diet assured 100% intake of all nutrients except energy (Table 1 ) when a reduced volume of chow was provided; energy density of the diet was reduced by subtracting corn starch content. ␤-Blockade groups were administered propranolol (DL-propranolol, Sigma) via drinking water. A graduated water tube was installed in each cage 7 days before the start of the experiment for measuring daily water intake. At day 0, based on the calculated average daily water intake (19 ml/day), 94.7 mg of propranolol/1 liter of water were distributed into the water tube to deliver 1.8 mg/day (for a 300-g rat) or 6 mg/kg body wt of propranolol. Over the 12-wk experimental period, daily water intake of each rat was measured, and concentration of propranolol in drinking water was adjusted to concentrations between 1.8 mg/16 ml and 1.8 mg/22 ml to deliver the goal dose. The dose of propranolol used was equivalent to that which, in previous studies, effectively mitigated loss of bone during disuse (4) . Dual-energy X-ray absorptiometry (DEXA) whole body scans and peripheral quantitative computed tomography (pQCT) scans of the tibia were performed while rats were anesthetized with an injectable cocktail of ketamine and medetomidine on day 0 and at weeks 4 and 12. Blood was drawn from a leg vein at day 0 and at weeks 4 and 12 (maximum volume 1.5 ml) while the rat was anesthetized for pQCT scans, and serum was saved at Ϫ80°C. On days 9 and 2 before death, animals were given subcutaneous injections of calcein (25 mg/kg) to label mineralizing bone for histomorphometric analyses. Left femora were fixed in 4% paraformaldehyde for immunohistochemistry (IHC) staining. Left tibiae were stored in 70% ethanol at 4°C for histology. All procedures in this study were approved by Texas A&M Institutional Animal Care and Use Committee.
Peripheral computed tomography and DEXA. The XCT Research M (Stratec, Norland, Fort Atkinson, WI) pQCT scanner has a scanning beam thickness of 500 m and was calibrated daily using a standard hydroxyapatite phantom. In vivo scans using a voxel size of 100 m were taken at the proximal tibia metaphysis with three transverse images at 5.0, 5.5, and 6.0 mm from the tibia plateau and from mid-shaft tibia at 50% total tibial length. A standardized analysis for either metaphyseal bone (contour mode 3, peel mode 2, outer threshold of 0.169 g/ml, inner threshold of 0.650 g/ml) or diaphyseal bone (separation 1, threshold of 0.650 g/ml) was applied to each slice. Values of total, cortical shell, and cancellous volumetric bone mineral density (vBMD) and cross-sectional total, cortical, and marrow areas were averaged across all slices to yield a mean value for each site. Machine precision (based on manufacturer's data) is Ϯ 3 mg/cm 3 for cancellous vBMD and Ϯ 9 mg/cm 3 for cortical BMD. Reproducibility in our laboratory for in vivo measures was determined from five repeat scans with repositioning of the animal between scans. Coefficients of variation for these measurements were Ϯ 1.24, 2.13, and 1.95% for in vivo proximal tibia total BMD, cancellous BMD, and total area, respectively.
Total BMD, bone mineral content (BMC), fat mass, and lean mass were measured by DEXA with a Lunar DPX-MD ϩ bone densitometer (GE Lunar, GE Medical Systems, Milwaukee, WI), with software standardized for small animals. Anesthetized rats were scanned while positioned prone on the platform; the tail was not included in total body scan. Daily densitometer standardization with a phantom spine varied by Ͻ0.1%.
Bone histomorphometry. Undemineralized distal left femora were subjected to serial dehydration and embedded in methylmethacrylate (Aldrich M5, 590-9). Serial frontal sections were cut 8 m thick and left unstained for fluorochrome label measurements; 4-m sections were treated with Von Kossa stain for measurement of cancellous bone volume and quantification of osteoblast, osteoid, and osteoclast surfaces. Histomorphometric analyses were performed with OsteoMeasure system (OsteoMetrics, Atlanta, GA) interfaced with a color video camera (DXC-390P, Sony) and an Olympus BX60 Microscope with epifluorescent light (Leeds Instruments, Irving, TX). At ϫ20, a defined region of interest was established ϳ1.0 mm from the growth plate and within the endocortical edges encompassing 6 -7 mm 2 . Total bone surface, single-labeled surface, and double-labeled surface were measured at ϫ100; interlabel distances, bone volume, and osteoid/osteoclast surface were measured at ϫ200. Mineral apposition rate (MAR; m/day) was calculated by dividing the average interlabel width by the time between labels (7 days), and mineralizing surface (MS/BS) for cancellous bone surfaces was calculated by using the formula MS/BS ϭ {[(single labeled surface/2) ϩ double label surface]/surface perimeter} ϫ 100. Bone formation rate was calculated as MAR ϫ MS/BS. Total bone, osteoid, and osteoclast surfaces were obtained by manual tracing. Derived indexes of bone volume/tissue volume referent (BV/TV), osteoid surface/bone surface (Os.BS), osteoclast surface/bone surface (Oc.BS), and osteoid thickness (Os.Th) were calculated using previously described formulae (3). Nomenclature for cancellous histomorphometry follows standard usage (36) . The number of marrow adipocytes was assessed, referring to standard bone marrow adiposity quantification protocol (17, 22) . Briefly, the number of adipocytes was manually counted at ϫ20 in a region of interest within the proximal femur beginning 1 mm distal to the growth plate and within the endocortical edges, encompassing a total of 6 -7 mm 2 . The number of adipocytes and osteoblastic cells positively stained for leptin were manually counted at ϫ20 in the same size region of interest within the proximal femur; only the highest quality sections (with no tearing or folding) could be used for these analyses, reducing the number of samples analyzed to four or five per group. Osteoblastic cells were defined as mononuclear cells adhering to a trabecular bone surface (including osteoid); most appeared to be either active osteoblasts or flatter bone lining cells (which are often described as quiescent osteoblasts). This excludes osteoclasts or other large marrow cells.
Immunohistochemistry and serum leptin analyses. Femur specimens from rats were fixed by immersion in 4% paraformaldehyde in 0.1 M PBS, pH 7.4. After 20 -24 h of fixation, samples were decalcified with 50% formic acid (by mixture with 20% sodium citrate, 1:1 ratio), then dehydrated in a graded series of ethanol and embedded in paraffin (Paraplast). Sections of the proximal femur (5 m thick) were immunostained for leptin by avidin-biotin technique (28) ; only the highest quality sections could be used for these analyses, reducing the number of samples analyzed to four or five per group. Tissue sections were deparaffinized, hydrated in PBS, and incubated in 0.3% H2O2 in distilled de-ionized water for 30 min at room temperature to block endogenous peroxidase activity. After being washed in PBS, the sections were pre-incubated with avidin D solution and then biotin solution for 15 min each, then with normal serum from the same species as the secondary antibody for 20 min at room temperature (to minimize background staining). Then they were incubated overnight at 4°C with primary rabbit polyclonal anti-leptin antibody [Ob (A20): sc-842, Santa Cruz Biotech, Santa Cruz, CA], diluted 1:500 in PBS/2% BSA, then with the corresponding biotinylated anti-rabbit IgG secondary antibody, made in goat, diluted by manufacturer's protocol in PBS/2% BSA/5% normal goat serum (NGS), and finally with ABC complex (avidin-biotin peroxidase complex) (Vectastain elite ABC reagent, VECTOR). Peroxidase activity was revealed by developing sections with enzyme substrate (NovaRED substrate kit, VECTOR). Sections were then counterstained with hematoxylin and examined for cells positively expressing leptin. Method specificity was tested by omitting the primary antibody in the immunostaining procedures as a negative control.
A rat leptin ELISA immunoassay kit (Crystal Chem, Chicago, IL) was used to measure the concentration of leptin in serum samples. Assays were run on duplicate samples. Precision coefficient of variation within-run was Ϯ3.2%, and coefficient of variation between run was Ϯ6. 4% .
Statistical analysis. To analyze pre-and posttreatment values of pQCT variables and serum leptin, a three-way ANOVA with repeated measures on time was used. In addition, a simple main-effects analysis within treatment group was performed when three-way interactions were significant and, when appropriate, Duncan post hoc or least significant difference tests were used within the simple main-effects analyses. To analyze the delta values (pre-post) of tibia pQCT variables and serum leptin and variables measured only at the end of the experiment (e.g., histomorphometric parameters), two-way ANOVA was used with post hoc testing as appropriate. Linear associations between change in serum leptin to the bone formation rate measured at the end of the experimental period were tested with Pearson's correlation coefficients. All values reported are means Ϯ SE.
RESULTS
Over the course of the 12-wk study, CON rats (ad libitumfed VEH and BB) consumed 15.3 Ϯ 2.7 g/day of the AIN-93M diet, whereas the two ER groups were fed by design 9.3 Ϯ 1.7 g/day of the modified AIN-93M-E diet. These intakes provided 58.6 Ϯ 10.5 and 34.8 Ϯ 6.3 kcal/day, respectively, for CON and ER rats ( Table 2 ) to achieve the intended 40% restriction of total energy intake. Food intake over the 12 wk was not different between VEH and BB rats within energy status groups. Energy density of the AIN-93M-E diet was lowered by reducing the primary carbohydrate source (corn starch) and replacing it with cellulose; hence the % of total kcal derived from bio-available carbohydrate was reduced to 60% vs. 76% in CON rats. Protein, fat, and important vitamin/mineral intakes were equivalent between the two groups ( Table 2 ). Due to reduced total energy intake, the relative contribution of protein and fat to total energy intake was higher in ER groups than in CON groups (24% vs. 14% for protein and 16% vs. 9% for fat, respectively). Water intake was measured daily to verify propranolol dosing and did not vary significantly among groups (16 -21.5 ml/day). Average propranolol dose delivered via water intake was 1.70 Ϯ 0.2 and 1.77 Ϯ 0.2 mg/day for CONBB and ERBB animals, respectively (P Ͼ 0.05 by unpaired t-test).
ER produces large decreases in fat mass, smaller decreases in total body mineral content, and preserved lean mass. ERVEH and ERBB rats had lower body weights than CONVEH and CONBB rats by week 2 of treatment and through the end of the experiment (Fig. 1A) . Over the 12-wk experimental period, ER rats' body weight declined to 249 Ϯ 12.63 g (Ϫ20%) in VEH-treated animals and to 254 Ϯ 3.73 g (Ϫ18%) in the BB-treated group (P Ͻ 0.0001 vs. week 0 within group), whereas CONBB rats gained body weight, weighing 347 Ϯ 6.44 g (ϩ10.4%) at 12 wk (P Ͻ 0.01 vs. week 0). The smaller weight gain (24 g) in CONVEH rats over 12 wk was not significant (P Ͻ 0.2). Over 12 wk, control VEH and BB rats CON, ad libitum fed; ER, energy restriction. *There was no significant impact of ␤-adrenergic blockade on food intake in CON and ER groups; hence, all animals' data within energy intake group were pooled for data in this table.
†Significant difference vs. CON (P Ͻ 0.001).
␤-Blockade Reduces Caloric Restriction Bone Loss • Baek K et al. gained fat mass (ϩ47% and ϩ64%, respectively), whereas ER VEH and BB rats lost significant amounts of body fat (Ϫ63% and Ϫ78%, respectively; P Ͻ 0.0001). After 12 wk, ER rats' fat mass was Ͻ20% than in CON animals (Fig. 1B) . However, there was no difference in lean body mass among groups at week 12 (Fig. 1B) , nor were there any significant changes in lean mass over time (data not shown). By week 12, total body BMD and BMC (by DEXA) in pooled ER groups were significantly lower than in pooled ad libitum-fed CON rats. Total body BMD and BMC decreased by 5% and 7%, respectively, in rats subjected to ER over the 12 wk (data not shown). ␤-Adrenergic blockade attenuates reduction of cancellous vBMD during ER. Longitudinal measures revealed a significant decrement by week 4 (Ϫ32 mg/cm 3 ; Ϫ12%) in proximal tibia cancellous vBMD compared with the initial value (day 0) in ER VEH rats; the cumulative deficit nearly tripled by the end of the experiment (Ϫ85 mg/ml; Ϫ22%).
Even though the significant reduction in cancellous vBMD was also observed in ERBB rats at week 12 (Ϫ16%) compared with their initial value, the impact of ER over 12 wk was significantly attenuated by BB treatment (Ϫ54 mg/ml vs. Ϫ85 mg/ml in ERVEH rats) (Fig. 2) (P Ͻ 0.05) . Total vBMD (including cortical shell and cancellous core) decreased over the experimental period in all groups by week 4 ( Table 3) . ER alone (Ϫ91.34 mg/cm 3 ), but not ER rats given BB (Ϫ62.68 mg/cm 3 ), resulted in significantly greater reduction in total vBMD than in CONBB and CONVEH rats (Ϫ36.00 and Ϫ33.28 mg/ml, respectively). Cortical shell vBMD in CONBB and ERBB rats (ϩ17 and ϩ19 mg/cm 3 , respectively) tended to increase over 12 wk (P Ͻ 0.07), but this increment was not observed in VEH-treated rats (data not shown). Longitudinal vBMD measurements at midshaft tibia revealed a significant and similar (ϳ2.0%) increment in cortical vBMD for all groups except ERVEH rats (P Ͻ 0.001), suggesting ER impairs age-related gains in cortical vBMD (Table 3) .
␤-Adrenergic blockade mitigates decreased cancellous bone formation and increased bone resorption during ER. The threefold decrease in %MS/BS observed with ER in vehicle-treated rats (vs. ad libitum-fed rats) was abolished by ␤-blockade (Fig. 3A) . Although MAR was numerically reduced in both ER groups vs. ad libitum-fed controls, this reduction was significant only in ERVEH rats (Fig. 3B ). These reductions in MAR and %MS/BS contributed to the 79% reduction in bone formation rate (Fig. 3C ) in ERVEH rats; this reduction in bone formation rate with ER was significantly attenuated in ERBB rats. Reduced % osteoid surface (vs. CONVEH) was observed in both ER groups (ERVEH and ERBB rats; Fig. 3D ). The twofold increase in % osteoclast surface observed in ERVEH rats was reversed in ERBB rats, which group mean was twofold lower than for ERVEH rats (Fig. 3E) . Percent BV/TV in ERVEH rats was 29% lower than that in CONVEH rats; ␤-adrenergic blockade normalized %BV/TV in ER animals (Fig. 3F) . No significant effects of ␤-adrenergic blockade on any histomorphometric parameter was observed in ad libitumfed CON rats.
␤-Adrenergic blockade mitigates decreased leptin localization on osteoblastic cells and increased marrow adiposity during ER. ER reduced the number of leptin-positive bone marrow adipocytes in vehicle-treated rats ninefold, but ␤-adrenergic blockade tended to abolish this reduction (Fig. 4, A-D 
Fig. 1. A: body weights over 12 wk of energy restriction (ER) or ad libitum fed (CON) in rats administered vehicle (VEH) or ␤-blocker (BB)
. For all experiment groups, n ϭ 10 except CONVEH, in which n ϭ 9. *Significant difference vs. CONVEH (P Ͻ 0.01). &Significant difference vs. CONVEH (P Ͻ 0.0001). #Significant difference vs. week 0 within group (P Ͻ 0.01). $Significant difference vs. week 0 within group (P Ͻ 0.001). %Significant difference vs. week 0 within group (P Ͻ 0.0001). B: total body fat mass and lean mass at week 12 from whole body DEXA scans. Fat mass portion of bars sharing same letters are not significantly different. Lean mass at 12 wk did not vary among the four groups. Table 4 ). The decline in the number of osteoblastic cells staining positive for leptin observed in ERVEH rats was not observed in ERBB rats (Fig. 4 , E-H); these comparisons did not, however, achieve statistical significance ( 2 ) (P Ͻ 0.05) (Fig. 4I) . There was no effect of ␤-adrenergic blockade on adipocyte number in ad libitum-fed controls.
␤-Adrenergic blockade mitigated decline in serum leptin during ER, and the change in serum leptin level was positively correlated with bone formation rate. The reduction in serum leptin values vs. week 0 values was significantly less in ERBB (Ϫ1.14 Ϯ 1.0 ng/ml) than in ERVEH (Ϫ5.31 Ϯ 1.1 ng/ml) animals by week 12 (Fig. 5A) . Changes in serum leptin over the experimental period were positively correlated with bone formation rate as measured in week 12 (r ϭ 0.62; P Ͻ 0.0001) (Fig. 5B) . Those rats exhibiting the greatest decline in serum leptin consistently had the lowest bone formation rate in distal femur cancellous bone. The absolute serum leptin level at week 12 also was associated with bone formation rate (r ϭ 0.54; P Ͻ 0.0001) (data not shown). Serum leptin level at week 12 normalized by fat mass (g) in ERBB rats (0.17 Ϯ 0.01 ng/ml·g fat) tended to be greater than that of ERVEH (0.07 Ϯ 0.02 ng/ml·g fat) (P Ͻ 0.07).
DISCUSSION
These experiments extend on previous work demonstrating interesting links between the sympathetic nervous system, regulation of serum leptin, and bone mass. To our knowledge, these are the first studies to demonstrate the impact of ␤-adrenergic blockade on alterations in cancellous bone mass, bone cell activity, marrow adiposity, and circulating leptin during prolonged ER. Our data demonstrate that blocking ␤-adrenergic signaling significantly mitigates reductions in metaphyseal cancellous vBMD and bone formation rate, abolishes the increased bone resorption, and attenuates the increase in marrow adiposity observed during ER in adult rats.
The propranolol dose used in this study (6 mg·kg Ϫ1 ·day Ϫ1 ) was chosen for its efficacy in preventing disuse-induced cancellous bone loss (4). Doses ranging from 0.1 to 5 mg/kg (intraperitoneal injection) of propranolol effectively prevent cancellous bone loss due to estrogen deficiency (after ovariectomy) (9) . We recently demonstrated that the ␤-adrenergic blocker propranolol mitigates disuse-induced bone loss by modulating changes in both resorption and formation; propranolol treatments are nearly as effective as providing a leptin analog in attenuating bone loss in tail-suspended male rats (4). Importantly, in the present study, no significant differences in any outcome measures were observed with ␤-adrenergic blockade in energy-replete control rats. ␤-Adrenergic blockade exerts its bone protective effect in the context of ER and/or serum leptin deficiency, but not in the energy-balanced state. We note that the relatively high variability in the ad libitum-fed (CON) cancellous vBMD values likely contributed to our inability to detect a statistically significant decline in energy-replete ani- mals given propanolol (Fig. 2) ; the magnitude of change in CON-BB cancellous vBMD suggests there may be a negative biological effect of ␤-adrenergic blockade in energy-replete animals. However, we observed no significant decline in histomorphometric measure of bone volume (%BV/TV; Fig. 3F ) in energy-replete rats given propranolol. Attenuated loss of bone mass by ␤-adrenergic blockade may result from suppressed resorption or attenuated decrease of formation or both, so we examined histomorphometric measures of formation and resorption. The large decreases in mineralizing surface and mineral apposition rate contributed to the nearly 80% reduction in bone formation rate due to ER; all these decrements were successfully attenuated by ␤-adrenergic blockade. Reduced bone formation rate was due more to reduction in %MS/BS rather than to changes in MAR, suggesting that declines in osteoblast recruitment rather than osteoblast activity per se were responsible for the reduced bone formation rate during ER.
The dramatic increase of bone resorbing surface observed in ER rats was abolished by propranolol treatment. Regulation of osteoclast number by ␤-adrenergic blockade could be mediated by the receptor activator of nuclear factor B-ligand (RANKL)/ osteoprotegerin (OPG) pathway. Previously published data demonstrate that ␤-adrenergic receptor agonist stimulates RANKL expression by osteoblasts and formation of osteoclasts in bone marrow/osteoblast co-culture; these changes are readily reversed by treatment with a ␤-adrenergic receptor antagonist (1) .
In the present study, 12 wk of ER lowered body weight and fat mass but markedly increased marrow adipocyte numbers, which was associated with reduced bone formation. Increased marrow adiposity may reflect a shift in bone marrow stromal cell differentiation pathways away from osteoblastic lineages toward adipocytes, effectively reducing availability of mature osteoblasts capable of forming bone matrix (5, 23, 48) . Recently published data demonstrate a similar dramatic increase in marrow adiposity with a similar (Ϫ30%) ER regimen, which also decreased bone mass and body fat in young growing mice (17) . Interestingly, we observed in the present study that the dramatic increase in adipocyte counts observed with ER was abolished by ␤-adrenergic blockade (Fig. 4I) . Given that body fat mass was not different between both ER groups (Fig. 1B) , further studies investigating the mechanism by which marrow fat is altered, whereas fat stores external to bone are not affected by ␤-adrenergic signaling blockade, are merited.
Our ER protocol did not result in any loss of lean mass. Given that 8-wk-old rats are fully mature, the lack of change in lean mass in ER rats is quite intriguing. Previously published data indicate that moderate, adult-onset ER can attenuate sarcopenia or aging-induced muscle loss in a primate model (6, 15, (32) (33) (34) . We have observed in separate studies higher lean mass in growing mice fed a 30% ER diet vs. that in ad libitum-fed animals (unpublished data). There is evidence that ER prevents the shift in muscle fiber-type distribution and delays cellular atrophy with aging (34), but further investigation is required to explain the underlying mechanisms for this phenomenon. Another possible explanation for lean mass loss in other protocols might be related to reduced absolute intake of protein; our rodent diets and feeding protocols were care- fully designed to provide the same absolute g protein intake for the 40% ER groups. Although serum leptin in humans and rodents correlates mainly with fat mass, several other factors modulate circulating leptin levels. In both human and rodent models, stimulation of the sympathetic nervous system and activation of ␤-adrenergic receptors in particular decrease serum leptin levels (25, 50) . The decline in circulating leptin with fasting is associated with activation of the ␤-adrenergic receptors and a decrease in insulin level (37, 47) . Long-term restriction in rats (ranging from 50% to 80% of ad libitum energy intake) results in a substantial decrease in serum leptin and white adipose leptin mRNA (30) . In the present study, ␤-adrenergic blockade had no apparent effect on the dramatic loss of body fat after 12 wk of moderate (Ϫ40%) ER, but it did mitigate the decline in serum leptin. Furthermore, changes in serum leptin over the experimental period were positively correlated with bone formation rate, which means the rats exhibiting the greatest decline in serum leptin had the lowest bone formation rate in distal femur cancellous bone. Propranolol-treated rats tended to have higher serum leptin per gram body fat as well, suggesting that leptin synthesis or release per unit adipocyte was greater when ␤-adrenergic signaling is blocked in ER rats. The exact mechanism for ␤-adrenergic blockade rescue of leptin synthesis or release is not clear. Stimulated adenylyl cyclase and subsequent PKA phosphorylation is thought to be the regulating mechanism of leptin release from adipose tissue. Elevated cyclic AMP inhibits leptin release by adipose tissue (20, 47) . We speculate that the positive effects of ␤-adrenergic blockade on mitigating bone loss with ER may derive from the synergistic effects of these two mechanistic pathways, that is, one from the direct effect of ␤-adrenergic blockade on osteoblasts and the other from the indirect effect of ␤-adrenergic blockade on leptin release from adipocytes, resulting in rescue of suppressed leptin synthesis or leptin release.
White adipose tissue is the primary site of leptin synthesis and secretory regulation, but recent data indicate that leptin is also produced in skeletal muscle, fetal bone/cartilage, and human osteoblasts (12, 26, 40, 49) . In the present study, leptin expression in bone marrow adipocytes and osteoblastic cells tended to be rescued in ER rats given propranolol; this group also exhibited mitigated reduction in serum leptin and cancellous bone mass. The hypothesis that ␤-adrenergic blockade increases leptin synthesis and/or release is consistent with the mitigated reduction in serum leptin we observed in propranolol-treated rats consuming less energy. But our data cannot address whether the leptin localizing to osteoblastic cells derives from nearby marrow adipocytes or from adipose tissue distant from bone or even derives from the osteoblastic cell itself. Further investigation on the effect of ␤-adrenergic blockade on expression, secretion, and potential autocrine signaling of leptin among bone cells is justified.
The impact of ER on the skeleton depends on both the duration of ER and the age of the animal. Previously published data indicate that in mice and rats the negative effect of ER on bone volume disappears if reduced energy intake continues past 1 yr of age. Furthermore, the higher bone mass observed in the energy-deprived animals (vs. ad libitum-fed controls) was maintained until the age of natural death during life-long ER (45) . On the other hand, the impact of 40% ER in young or growing mice is generally negative, with decreases in cortical but not always cancellous bone mass in 3.5-to 6-mo-old mice, along with significant declines in lean mass, fat mass, serum leptin, and IGF-I (24). However, separate studies using much younger mice (3-to 12-wk-old) demonstrated decrements in both cortical and cancellous bone mass, along with significant increases in marrow adiposity (17) . The present study, performed in female rats subjected to ER between 6 and 9 mo of age, demonstrates significant decrements in cancellous bone mass with minimal effects on mid-shaft cortical bone. It may be that age-or species-specific alterations in important endocrine factors or in bone marrow stromal cells differentiation Change in serum leptin (ng/ml)(wk12-wk0) Values are means Ϯ SE (no. of positive-stained cells/mm 2 ). No significant differences were found among groups by ANOVA.
capability could explain some of these bone compartmentspecific differences.
One limitation of this study design is the altered macronutrient content of the ER diet. Following the approach of many rodent ER studies (13) , energy content of the diet was achieved by reducing the carbohydrate content of the diet, replacing it with cellulose. We are unaware of any data suggesting that this magnitude reduction in CHO as % total kcal (60% vs. 76% in ad libitum-fed controls) has an independent effect on bone formation or resorption dynamics.
In summary, 40% ER over 12 wk in adult rats caused significant bone loss and marrow adiposity at the proximal tibia accompanied by reductions in circulating leptin. ␤-Adrenergic blockade mitigated the ER-induced bone loss by attenuating declines in osteoblastic cell recruitment and activity and by abolishing increases in osteoclast surfaces. Propranolol treatment also mitigated the increase in marrow adiposity and reduced circulating leptin observed after ER. Reduction in serum circulating leptin and in leptin expression in bone marrow adipocytes and osteoblastic cells with ER was mitigated by ␤-adrenergic blockade. Taken together, these data suggest a strong role for ␤-adrenergic signaling from the SNS in the response of cancellous bone and marrow fat to reduced dietary energy intake.
Growing evidence suggests an association between use of ␤-blockade medications and reduced fracture risk in humans. Chronic use of ␤-blocker medications is associated with lower femoral neck fracture risk, probably by improving BMD, cortical bone geometry, and trabecular bone microarchitecture in postmenopausal women (8) . Our results suggest that individuals using ␤-blocker medications to treat existing cardiovascular disease, who are often advised to lose weight as well, may benefit additionally if bone loss incurred during chronic ER is simultaneously mitigated.
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